Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis

被引:0
|
作者
Scorza, R [1 ]
Rivolta, R [1 ]
Mascagni, B [1 ]
Berruti, V [1 ]
Bazzi, S [1 ]
Castagnone, D [1 ]
DiPalo, FQ [1 ]
机构
[1] UNIV MILAN, CATTEDRA IMMUNOL CLIN & ALLERGOL,OSPED MAGGIORE, IRCCS,DIV NEFROL, I-20122 MILAN, ITALY
关键词
scleroderma; iloprost; nifedipine; color Doppler ultrasonography;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To investigate the effect of iloprost, a stable prostacycline analog, on kidney blood flow in patients with systemic sclerosis (SSc), using color flow Doppler sonography. Methods. The acute effect of the drug was studied in 10 patients with SSc with elevated resistance index (RI) levels (all RI values reported are multiplied by 100). Iloprost was administered intravenously (2 ng/kg/min for a period of 8 h). To study the effects of chronic drug administration, 16 patients with SSc were randomly assigned to 2 groups of 8 cases each. The first group was treated with 9 infusions of iloprost in 6 mo. The second group was treated with slow release nifedipine (40 mg/day) for 6 mo. Results. Interlobar artery RI (median 67 vs 61; p = 0.02) and cortical vessel RI (median 65 vs 54; p = 0.001) were reduced after acute treatment. In chronic drug administration, RI values were not modified by nifedipine, while iloprost reduced the RI of the interlobar (median 69 vs 61; p < 0.03) and cortical arteries (median 66 vs 58; p < 0.01). Conclusion. Our findings suggest iloprost might be useful for treatment of scleroderma renal vasospasm.
引用
收藏
页码:1944 / 1948
页数:5
相关论文
共 50 条
  • [41] Gene expression profiling in circulating endothelial cells from systemic sclerosis patients shows an altered control of apoptosis and angiogenesis that is modified by iloprost infusion
    Elisa Tinazzi
    Marzia Dolcino
    Antonio Puccetti
    Antonella Rigo
    Ruggero Beri
    Maria Teresa Valenti
    Roberto Corrocher
    Claudio Lunardi
    Arthritis Research & Therapy, 12
  • [42] Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis
    Sharma, Shefali
    Chattopadhyay, Arghya
    Jain, Siddharth
    Dhir, Varun
    Prakash, Mahesh
    Rathi, Manish
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [43] Gene expression profiling in circulating endothelial cells from systemic sclerosis patients shows an altered control of apoptosis and angiogenesis that is modified by iloprost infusion
    Tinazzi, Elisa
    Dolcino, Marzia
    Puccetti, Antonio
    Rigo, Antonella
    Beri, Ruggero
    Valenti, Maria Teresa
    Corrocher, Roberto
    Lunardi, Claudio
    ARTHRITIS RESEARCH & THERAPY, 2010, 12 (04)
  • [44] INTRAVENOUS ILOPROST INFUSION IN PATIENTS WITH RAYNAUD PHENOMENON SECONDARY TO SYSTEMIC-SCLEROSIS - A MULTICENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND-STUDY
    WIGLEY, FM
    WISE, RA
    SEIBOLD, JR
    MCCLOSKEY, DA
    KUJALA, G
    MEDSGER, TA
    STEEN, VD
    VARGA, J
    JIMENEZ, S
    MAYES, M
    CLEMENTS, PJ
    WEINER, SR
    PORTER, J
    ELLMAN, M
    WISE, C
    KAUFMAN, LD
    WILLIAMS, J
    DOLE, W
    ANNALS OF INTERNAL MEDICINE, 1994, 120 (03) : 199 - 206
  • [45] Progressive Loss of Lymphatic Vessels in Skin of Patients with Systemic Sclerosis
    Manetti, Mirko
    Milia, Anna Franca
    Guiducci, Serena
    Romano, Eloisa
    Matucci-Cerinic, Marco
    Ibba-Manneschi, Lidia
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (02) : 297 - 301
  • [46] THE EFFECT OF SILDENAFIL AND ILOPROST ON CXCL10 LEVEL IN SYSTEMIC SCLEROSIS: IN VIVO AND IN VITRO COMPARISON
    Antinozzi, C.
    Corinaldesi, C.
    Marampon, F.
    Riccieri, V.
    Valesini, G.
    Vasile, M.
    Lenzi, A.
    Del Galdo, F.
    Crescioli, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1057 - 1057
  • [47] Evaluation of choroidal vascularity index in systemic sclerosis patients
    Atas, Ferdane
    Kaya, Mahmut
    Ayhan, Ziya
    Ozkan, Ozlem
    Birlik, Merih
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2023, 41
  • [48] COMPARATIVE PHARMACOKINETICS OF ILOPROST (I) IN PATIENTS WITH RAYNAUDS PHENOMENA SECONDARY TO SYSTEMIC-SCLEROSIS (RPS)
    HINDERLING, PH
    SISTA, SM
    SEIBOLD, J
    WIGLEY, F
    WISE, RA
    HOLYOAK, W
    KOZIOL, T
    DOLE, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (02) : 133 - 133
  • [49] Is there a disease-modifying effect of long-term cyclic iloprost therapy in systemic sclerosis?
    Airo, P.
    Scarsi, M.
    Danieli, E.
    Rossi, M.
    Grotto, A.
    Zambruni, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 197 - 197
  • [50] Antioxidant status after iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis
    Alexandra Balbir-Gurman
    Yolanda Braun-Moscovici
    Vladimir Livshitz
    Daniel Schapira
    Doron Markovits
    Alexander Rozin
    Tatiana Boikaner
    A. Menahem Nahir
    Clinical Rheumatology, 2007, 26 : 1517 - 1521